Drug Profile


Alternative Names: Akatinol; Axura; Ebixa; Extended-release memantine capsules - Forest Laboratories; Memary; Namenda; Namenda XR; SUN Y7017; SUNY 017

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Childrens Medical Center Corporation
  • Developer Allergan; Daiichi Sankyo Company; Forest Laboratories; Lundbeck A/S; Merz Pharma; Neurobiological Technologies; University of California, Davis
  • Class Amines; Analgesics; Antidementias; Antiparkinsonians; Antispastics; Antitussives; Organic bridged compounds; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Dementia
  • Discontinued Asperger syndrome; Autistic disorder; Diabetic neuropathies; Fragile X syndrome; Glaucoma; Neuropathic pain; Vascular dementia

Most Recent Events

  • 29 Mar 2016 Daiichi Sankyo plans a phase III trial for Alzheimer's disease in Japan (IV) (JapicCTI-163209)
  • 15 Mar 2016 Biomarkers information updated
  • 26 Feb 2016 Clinical trials in Alzheimer's disease (Combination therapy) in Japan (PO) (Daiichi Sankyo and Katayama Medical Clinic plans a clinical trial for Alzheimer's disease (Combination therapy) in Japan (UMIN000021140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top